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This study explored the genetic basis of the combination of extreme blood levels of HDL-C and LDL-C, a well-
studied endophenotype for CVD, which has several attractive features as a target for genetic analysis: (1) the
trait is moderately heritable; (2) non-genetic risk factors account for a signiﬁcant but still limited portion of
the phenotypic variance; (3) it is known to be moderated by a number of gene products. We exhaustively
surveyed 11 candidate genes for allelic variation in a random population-based sample characterized for
known CVD risk factors and blood lipid proﬁles. With the goal of generating speciﬁc etiological hypotheses,
we compared two groups of subjects with extreme lipid phenotypes, from the same source population, using
a case–control design. Cases (n¼ 186) were subjects, within the total sample of 1708 people, who scored in
the upper tertile of LDL-C and the lowest tertile of HDL-C, while controls (n¼ 185) scored in the lowest tertile
of LDL-C and the upper tertile of HDL-C. We used logistic regression and a four-tiered, systematic model
building strategy with internal cross-validation and bootstrapping to investigate the relationships between
the trait and 275 genetic variants in the presence of 10 non-genetic risk factors. Our results implicate a subset
of nine genetic variants, spanning seven candidate genes, together with ﬁve environmental risk factors, in the
etiology of extreme lipoprotein phenotypes. We propose a model involving these 14 genetic and non-genetic
risk factors for evaluation in future independent studies.
INTRODUCTION
Cardiovascular disease (CVD) risk is influenced by several
well-established risk factors, such as body mass index (BMI),
an indicator of overweight and obesity, blood lipids, diabetes, and
blood pressure (1). These are intermediate phenotypes, correl-
ated among themselves (1) and having their own genetic and
environmental determinants, including diet (2,3), nutrition (4),
hormones (5,6), smoking (7), alcohol intake (8), and physical
activity (9,10).
Studies in humans and mice indicate that both the type and
quantity of blood-borne lipids are predictive of cardiovascular
health or disease and that a relatively large number of proteins
is involved directly or indirectly in the transport, maintenance
and elimination of blood lipids, including high and low density
lipoprotein cholesterol (HDL-C and LDL-C, respectively)
(11–15). We identified 11 of these proteins (depicted in
Fig. 1) with a well-known collective activity in the reverse
transport of cholesterol from peripheral cells to the liver. Genes
coding for these proteins that have been implicated with blood
lipids comprise: ATP-binding cassette protein 1 (ABCA1) (16);
apolipoprotein A1 (APOA1) (17); apolipoprotein E (APOE)
(18,19); cholesterol-ester transfer protein (CETP) (20–22);
endothelial lipase (EL) (23); hepatic lipase (HL) (24); lecithin–
cholesterol acetyl transferase (LCAT) (25); low density
lipoprotein receptor (LDLR) (26); lipoprotein lipase (LPL)
(27,28); phospholipid transfer protein (PLTP) (29); and
scavenger receptor class B type I (SR-BI) (30). With the
possible exceptions of APOE and LPL, the vast majority of
studies attempting to correlate candidate gene variants with
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common, heritable traits have yielded either false positive
findings, or else real but weak genotype–phenotype associa-
tions. This shortcoming is inherent in association studies based
on limited numbers of candidate gene variants (31–34). In an
attempt to overcome this limitation, Knoblauch et al. (35) typed
29 SNPs in six genes (APOE, CETP, HL, LCAT, LDLR, LPL)
among 732 subjects from 222 nuclear families and analyzed
haplotypic effects. The associations between each gene and
blood lipoproteins were more significant for haplotypes than
for single nucleotide polymorphisms (SNPs).
In the present study we explore the associations between the
11 target genes shown in Figure 1 and blood HDL-C and LDL-C
concentrations. We made no attempt to model the reverse
cholesterol transport (RCT) pathway, per se.However, in contrast
to Knoblauch et al. (35), we combined the variants across the
11 genes in our statistical models. Moreover, since statistical
power to detect lipid-related genetic variation may be reduced
when the confounding effects of known non-genetic risk factors
are not taken into account, we advantageously measured
genotypic variation in a sample that had been characterized
in detail for established CVD risk factors.
We considered using as phenotypes HDL-C, LDL-C or
triglycerides (TG) individually, or some combination of all
three. We opted finally for a combination of HDL-C and LDL-C
because some of the protein products of the 11 target genes are
implicated in the regulation of both HDL-C and LDL-C levels.
It could be argued that selection upon either HDL-C or LDL-C
alone would have provided a less complex, more genetically
homogeneous phenotype, but the choice of one or the other
measure might have captured only part of the combined
phenotypic effects of the targeted genes. We systematically
surveyed exons for major allelic variants in a subsample of
95 subjects. We then compared the allelic and genotypic
distributions of the ensuing collection of polymorphic variants
(mostly SNPs) in two groups of subjects with extreme lipid
phenotypes, from the same source population, using a case–
control study design. Cases were those 186 individuals who,
within a total sample of 1708 people, scored in the upper tertile
Figure 1. Graphical representation of the reverse cholesterol transport (RCT) metabolic pathway, from which we selected 11 genes: ABCA1, APOA1, APOE,
CETP, EL, HL, LCAT, LDLR, LPL, PLTP and SR-BI. Dietary free fatty acids and monoglycerides form triglycerides (TG) in the intestine, which are transported
by chylomicrons. TG are also transported as very low-density lipoproteins (VLDL) formed in the liver. LPL releases free fatty acids from chylomicrons and VLDL
in peripheral tissues (heart, muscle, adipose). The TG-depleted ‘chylomicron remnants’ take on APOE and serve, in the macrophages, as a basis for the construc-
tion of APOA1 and APOE-containing HDL particles. These nascent HDL particles interact with peripheral cells and acquire cholesterol and phospholipids through
a transport process facilitated by ABCA1. Nascent HDL evolves into mature HDL in part via the PLTP-mediated transfer of phospholipids and free cholesterol
from TG-rich lipoproteins to HDL, and via the esterification of free cholesterol within the HDL particle by the LCAT enzyme. These cholesteryl esters (CE) form
the core of the mature HDL, which can be further enriched with APOE prior to their uptake as particles in the liver. CEs can also be selectively transferred,
in exchange for TG, to TG-rich lipoproteins through the action of CETP. These TG-rich lipoproteins can then undergo hepatic endocytosis via the action of
LDL-receptors. HL and EL hydrolyze HDL-TG and phospholipids, thereby reducing the size of HDL and stimulating the SR-BI-mediated selective hepatic uptake
of CE.
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of LDL-C and the lowest tertile of HDL-C distributions, while
controls (n¼ 185) scored in the lowest tertile of LDL-C and
the upper tertile of HDL-C distributions. The case–control
subjects also tended to score in the corresponding extreme
tertiles of TG, because HDL-C, LDL-C and TG levels are
highly correlated in the extreme tails of their distributions. All
the analyses were simultaneously adjusted for known non-
genetic cardiovascular risk factors, and the remaining residual
variance was modeled using an analytic strategy starting with a
total of 275 genetic variants spanning the 11 candidate genes.
RESULTS
For ease of reference, Table 1 provides a flowchart of the steps
involved in obtaining the results described in this section and
indicates (see last column) the tables and figures where detailed
data are shown either in the paper or in its Appendix on the
authors’ web site (www.epidemiology.ch, choose ‘publications’).
Resequencing: identification and
characterization of SNPs
A total of 275 SNPs were identified (Table 2 and Appendix
Table A). Of these, 190 (69%) mapped to introns, flanking
regions, or 50 and 30 flanking/untranslated regions (UTR), while
85 (31%) mapped to exons. Among the exonic SNPs, 34 (40%)
coded for non-synonymous amino acids. There were 139 (51%)
‘common’ SNPs with rare allele frequency 3%. Nucleotide
diversity (104) was 7.2 overall, but 10.5 in promotor, 6.5 in
exons, 7.7 in introns, 7.4 in 30-UTR and 7.7 in 50-UTR
sequences (36).
Comparison of resequencing and remaining case–control
sample rare allele frequencies
Excluding the nine LDLR SNPs retrieved from a public
database plus nine other resequenced common SNPs that could
not be assayed in the remaining cases and controls for technical
reasons, 121 of the 139 common SNPs could be compared
between the resequencing subsample and the remaining case–
control sample. The rare allele frequencies of these 121 SNPs
were very similar in these two groups (frequency difference
between the n¼ 95 resequencing sample and the n¼ 276
remaining case–control sample: median¼ 0%, Wilcoxon
signed-rank test P¼ 0.26; histogram in Appendix Figure A).
Non-genetic characteristics and lipid profiles of
the case–control sample
Detailed distributions of the categorical and continuous
nongenetic covariates among the 186 cases and 185 controls
have been presented recently elsewhere (37). As expected due
to extreme phenotypic selection, the cases were heavier, less
educated, more sedentary, and, on average, 4 years older (all
P< 0.03). These factors were included as confounders in the
analyses. Cases had also higher total cholesterol (mmol/l:
cases, 6.61; controls, 5.01, P< 0.0001) and higher TG
(geometric mean: cases, 1.55; controls, 0.85, P< 0.0001).
Comparison of case–control sample and
excluded subjects
A comparison of the final case–control sample (n¼ 371) versus
the 79 extreme phenotypic subjects who were excluded due to
insufficient blood samples remaining for DNA analyses is
shown in Table 3. Apart from being more sedentary (76 versus
63%, P< 0.03), the excluded subjects were very similar to the
final case–control sample on all the other non-genetic
characteristics and lipid profile measurements investigated.
It is unlikely that this observed difference in sedentarity
prevalence would modify the results substantially because
sedentarity was not a major confounder in the analyses.
Single-SNP association study
In our first analysis step (tier 1 modeling) we identified individual
SNPs which were distributed differently in cases and controls,
after adjustment for the nongenetic factors. First in tier 1a, of the
130 valid common SNPs, 51 had individual, adjusted case–
control odds ratios (ORs) either 1.50 (‘atherogenic SNPs’), or
1/1.50¼ 0.67 (‘atheroprotective SNPs’), independently of
statistical significance, or had an SNP gender interaction
(nominal), P 0.10, and fulfilled at least one of the first two
conditions for men or women or both (most often differently in
each gender) (‘gender-dependent SNPs’, overriding the other two
groups). Then in tier 1b we excluded one SNP from each pair of
highly correlated SNPs, and were also forced to eliminate SNPs
with rare allele frequencies <5% because their regression
coefficients were unstable in the logistic models. At the end
of tier 1, 37 SNPs were eligible for multi-SNP analyses
(10 atherogenic þ 17 atheroprotective þ 10 gender-dependent
SNPs). These 37 common SNPs comprised 13 exonic [nine
coding (six non-synonymous þ three synonymous)] and 24
non-exonic SNPs (Appendix Table B).
Multiple SNP association study
In our second analysis step (tier 2 modeling) we eliminated
statistically redundant SNPs (only) using stepdown selection
within each of the three tier 1 SNP groups from logistic models
(the non-genetic covariates were forced to remain in the three
models). There were six atherogenic þ eight atheroprotective þ
six gender-dependent SNPs retained after tier 2 (Table 4).
In our third analysis step (tier 3 modeling) we pooled the 20
retained SNPs from tier 2 across all three SNP groups and
performed a further stepdown selection of SNPs only (non-
genetic covariates again forced to remain in the logistic three
models). There were one atherogenic þ six atheroprotecti-
ve þ three gender-dependent SNPs retained after tier 3
(Appendix Table D).
In our fourth analysis step (tier 4 modeling) the 10 SNPs
retained after tier 3 became eligible for the final model, but they
competed with each other and with the 10 non-genetic covariates
in the final stepdown selection. The tier 4 final model (see
below) comprised nine SNPs (þtwo SNP gender interactions)
and five non-genetic factors (BMI, gender, alcohol, current
smoking, age). In the cross-validation, there was considerable
overlap between the five 80% random subsample SNPs and the
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Table 1. Steps of gene selection, population sampling, and statistical modeling strategy for reverse cholesterol transport (RCT) SNP data (numbered tables/figures/references are in the text; lettered tables/
figures are in the Appendix)
Step Content Number of remaining SNPs Number of eliminated SNPs See
RCT genes Define biological model based on 11 genes — — Figure 1
Population-based random sample Men and women residents of Geneva, Switzerland,
ages 35–74 years, 1999–2000 (n¼ 1708 untreated
for hypercholesterolemia)
— — References (9,44)
Blood lipid extreme phenotype
case–control sample
Combined HDL-C and LDL-C tertile groups:
186 cases—low HDL-C þ high LDL-C;
185 controls—high HDL-C þ low LDL-C
[n¼ 371 (¼ 4507 79 excluded)].
— — Table 3
Statistical power (186 cases þ 185 controls) — — Figure B
SNP detection Resequencing of 50, 30 flanking/UTR regions and
all exons in subsample of cases þ controls (n¼ 95).
Public database SNPs for LDLR
256
19
Total¼ 275
—
—
—
Table A
Reference (47)
Tables 2 þ A
Genotyping All common SNPs (3%) assayed in remaining cases
and controls (n¼ 276).
Valid genotyping.
Comparison of allele frequencies for resequenced (n¼ 95)
versus genotyped data (n¼ 276)
139
130
121 (all genes but LDLR)
136
9
—
Table A
Figure A
Tier 1a modeling before Tier 1b
exclusions
Retain SNPs with adjusted single-SNP case–control
OR 1.50 or OR 0.67
(see below)
Total 51 79 Table B
Tier 1aa SNP groups Atherogenic (AG) (OR 1.50); atheroprotective
(AP) (OR 0.67); gender-dependent (GD) (see text)
AG: 14
AP: 23
GD: 14
—
—
— Table B
Tier 1ba exclusions
(multicollinearity)
Eliminate one SNP when jrj  0.7, within or between
the AG, AP, GD SNP groups
AG: 12
AP: 18
GD: 13
2
5
1
Table B
Tier 1ba exclusions (rare SNPs) Eliminate rare SNPs (rare allele 5%) within the
AG, AP, GD SNP groups
AG: 10
AP: 17
GD: 10
2
1
3
Table B
Tier 1a modeling Total SNPs after tier 1b exclusions Total 37 Total 14 Table B
Tier 2a modeling Within AG, AP, GD groups (nominal) P¼ 0.10 stepdown
selection of SNPs (10 non-genetic covariates forced into models)
AG: 6
AP: 8
GD: 6
Total 20
4
9
4
Total 17
Tables 4 þ C
Tier 3a modeling Pool tier 2 SNPs across AG, AP, GD groups. Stepdown SNP
elimination (nominal P¼ 0.05) (10 non-genetic covariates
forced into model)
AG: 1
AP: 6
GD: 3
Total 10
5
2
3
Total 10
Tables 4 þ D
Tier 4a modeling Stepdown elimination (nominal P¼ 0.05) of 10 Tier 3 SNPs
and 10 non-genetic covariates.
Bootstrap final model.
Cross-validate case-control predictionsb
AG: 1
AP: 5
GD: 3
Covariates: 5
9 SNPs þ 5 covariates
9 SNPs þ 5 covariates
0
1
0
Covariates: 5
1 SNP þ 5 covariates
1 SNP þ 5 covariates
Table E
Table 5
Table 6
Tiers 1–4a modeling Cross-validate entire modeling processa — — Tables B, C, D
AG, atherogenic SNPs, AP, atheroprotective SNPs; GD, gender-dependent SNPs.
aTiers 1–4 models internally cross-validated in five random subsamples each comprising 80% of the subjects.
bTier 4 model case–control predictions internally cross-validated in five random subsamples each comprising 20% of the subjects excluded from modeling. Appendix tables and figures are on the authors’ web
site: www.epidemiology.ch, choose ‘publications’.
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total sample SNPs within each of the four modeling tiers
(Appendix Tables C, D and E).
Final multi-SNP logistic model
The final tier 4 bootstrap-estimated ORs and confidence
intervals are presented in detail in Table 5. The nine retained
SNPs spanned seven genes. Each SNP was associated with
case–control status over and beyond the associations of the
nongenetic factors. The two gender-dependent SNPs exhibited
qualitatively different associations by gender: HL 3b279 was
protective in men (OR¼ 0.34, P< 0.04), but not in women
(OR¼ 2.86, P¼ 0.13), while SR-BI A350A was protective
in men (OR¼ 0.28, P< 0.04), but borderline deleterious in
women (OR¼ 4.98, P¼ 0.053).
That our adjustment procedures increased the statistical
power to detect SNP effects in this study was demonstrated by
refitting and bootstrapping the final model with the nine SNPs,
but without the non-genetic covariates other then gender.
Except for the two bootstrapped gender-dependent SNP
unadjusted ORs for women (HL 3b279: 1.34; SR-BI
A350A: 2.25), all of the other unadjusted SNP ORs were
biased towards unity (APOE2: 0.24; PLTP 1bþ26: 0.60;
ABCA1 50b.3038: 0.41; LPL S447X: 0.46; ABCA1 32bþ30:
2.38; LDLR2: 0.61; HL 1b280: 0.54; HL3b279 for men:
0.63; SRBI A350A for men: 0.36). The latter unadjusted
estimates were as much as two times smaller than their adjusted
counterparts, although all of them still had bootstrapped
P< 0.05. On the other hand, four of the unadjusted SNPs
(including the HL and SR-BI exceptions for women) had
bootstrapped P> 0.05 (PLTP 1bþ26: P¼ 0.09; LDLR2:
P¼ 0.13, HL 3b279 for women: P¼ 0.62; SRBI A350A
for women: P¼ 0.12).
Also of note, the cross-validation subsample models tended
to retain ABCA1 1b1126 (þgender interaction) instead of the
HL and SR-BI SNPs (þgender interactions). It was not
surprising, given the statistical power of the study, that the
largest modeling discrepancies occurred for gender-dependent
SNPs. Augmenting the tier 4 model with ABCA1 1b1126
(þ gender interaction) resulted in much-attenuated associations
for the two HL SNPs. Thus, although Table 5 shows the
most parsimonious, best model derived from the total case–
control sample, the cross-validation results suggested that
the selection of ABCA1 1b1126 versus the two HL SNPs
may be sample-specific.
Overall, the final tier 4 logistic model accounted for 60% of
the case–control variance, correctly classifying 79% of the
cases and 78% of the controls. The respective mean
classification rates for the five cross-validation subsamples
were 72 and 76% (Table 6). As discussed in further detail
below, the finalmodel needs to bevalidated in a future independent
sample. The non-genetic risk factors were associated with
phenotype as expected based upon previous findings, which
suggestively bodes well for the general applicability and putative
significance of our findings once an independent replication of
our model is obtained. However, we caution that development
of an appropriate permutation test to correct for possible
multiple testing artifacts, or better, replication in an independent
sample, will be required to finally address questions of statistical
significance.
Swiss-born subjects only
In order to assess potential population stratification effects on
the findings, we refitted the final tier 4 model to the Swiss-born
subjects only, who comprised over half the sample (76 cases
and 89 controls with complete data). With the exception of the
SNP gender interaction terms for HL 3b279 and SR-BI
A350A, which had to be omitted because of small sample
sizes, both the magnitudes and directions of all the SNP main
effect OR associations among the Swiss-born subjects were
entirely consistent with those based on all subjects (not shown
in a table).
DISCUSSION
This study explored the genetic basis of the combination of
extreme blood levels of HDL-C and LDL-C, a well-studied
endophenotype for CVD, which has several attractive features as a
target for genetic analysis. First, the trait is known to bemoderately
Table 2. Eleven reverse cholesterol transport (RCT) genes and numbers of SNPs assayed
Genes SNPs assayed
Acronym Name GenBank no. Chromosome position Numbers of exons Totala Exonic Coding Intronic Commonb
ABCA1 ATP-binding cassette 600046 9q22–q31 50 88 19 4 69 53
APOA1 Apolipoprotein A–I 107680 11q23 4 4 1 1 3 2
APOE Apolipoprotein E 107741 19q13.2 4 7 3 2 4 5
CETP Cholesteryl ester transfer protein 118470 16q21 16 27 8 5 19 14
EL Endothelial lipase 603684 18q12.1–q12.3 10 31 4 3 27 15
HL Hepatic lipase 151670 15q21–q23 9 37 17 7 20 15
LCAT Lecithin–cholesterol acetyl transferase 245900 16q22.1 6 4 2 0 2 2
LDLR Low-density lipoprotein receptor 143890 19p13.2 18 19 12 3 7 9
LPL Lipoprotein lipase 238600 8p22 10 24 9 3 15 13
PLTP Phospholipid transfer protein 172425 20q12–q13.1 12 17 4 3 13 6
SR-BI Scavenger receptor class B type I 601040 Chr. 12 13 17 6 3 11 5
Totals 152 275 85 34 190 139
aExcept for LDLR (see text), all SNPs were identified by resequencing a subsample 95 subjects (see text).
bWith nine exclusions for technical reasons, 130/139 common SNPs (rare allele frequency 3%) were assayed in 371 subjects with extreme lipid phenotypes.
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heritable. In German twins, heritability was 0.61 for HDL-C and
0.59 for LDL-C (38). Second, non-genetic risk factors account for
a significant but still limited portion of the phenotypic variance.
And third, intense biochemical and physiological investigations
have identified a number of genes whose protein products have
impacts on HDL and LDL bound cholesterol.
This is perhaps the first time that some ordering of the
relative contributions of both genetic and non-genetic variables
to the total variance of a lipid trait has been demonstrated. Nine
SNPs (across seven genes) and five non-genetic factors
remained associated with the extreme phenotypic lipid profiles
in the final, most parsimonious model. BMI was the single
most important determinant of ‘caseness’, with an adjusted r2
of 0.27. Next in importance were APOE2 (þ0.05 to cumulative
r2) and PLTP 1b.þ26 (þ0.03), followed by (mostly low to
moderate) alcohol drinking (þ0.07) and (current) cigarette smoking
(þ0.03). After ABCA1 50b.3038 (þ0.03 to cumulative r2)
and LPL S447X (þ0.02), age (þ0.01) and gender (þ0.02) were
added. From a biological perspective, the selected nongenetic
factors make sense. Obese patients typically have dyslipidemia (4).
Approximately half of the protective effect of alcohol may be
mediated through increased levels of HDL-C (8). Smoking is
associated with lower HDL-C and higher LDL-C (7). There are
well-established age and gender-related differences in lipid
metabolism, endothelial function, and risk of atherosclerosis (5).
Our results also reflect the careful selection of biologically relevant
candidate genes, and the effective conditioning of their putative
effects upon known risk factors. They are consistent with our
previous findings using single candidate gene approaches in the full
n¼ 1708 sample, either for the association of APOE with HDL-C
(9), or for the non-association of the SNP in position 629 of the
promotor region of CETP with either HDL-C or LDL-C (39).
The case–control design based on phenotypically extreme
subjects is a critical element of the study and merits several
comments. Cases represented just over 10% of our sample with
the most atherogenic HDL-C and LDL-C profiles, while
controls comprised just over 10% of the most atheroprotective
HDL-C and LDL-C profiles. For a fixed sample size, this
design has more statistical power to detect genetic effects for
the selected trait than one based on the total sample (40). The
reason is that marginal effects estimated from the comparison
of subjects with extreme phenotypes are likely to incorporate
epistasis or interactions between genes and covariates, if these
exist, biasing effect sizes upward (41). The statistical power to
detect individual SNP effects is therefore increased. On the
other hand, the absence of subjects with intermediate
phenotypes reduces the statistical power to test for epistasis
that may contribute to the phenotypic variation. Given the
modest sample size of our study we therefore did not attempt
to study gene–gene or gene–covariate interactions, except
for gender which we planned by design. Had it been feasible
to conduct our case–control study with a much larger sample,
the outset of the analysis would have been the most appropriate
stage at which to assess epistasis and would have involved
all 130 common SNPs. We are currently working on ways
to address this problem in a non-selected sample, but to the
best of our knowledge it remains unsolved and most
studies focusing on even a limited number of SNPs have
not adequately addressed the issues of gene–gene and
gene–environment interactions.
The current study had several salient strengths. The
population-based random sample was selected from 1708
residents of Geneva, Switzerland, each of whom was evaluated
for known risk factors for CVD and atherogenic lipid profiles.
Methods to measure several of these factors were developed
and validated in the same target population (42,43). The protein
products of each of our 11 candidate genes were known to
affect blood cholesterol levels. We completely sequenced the
coding portion of each candidate gene (a total of 152 exons)
along with the immediately adjacent non-coding DNA
segments corresponding to both the 50 and 30 regions of each
gene in a subset of 95 individuals to enhance the identification
of common gene variants. We analyzed in the case–control
study an exhaustive set of candidate genetic variants (130 SNPs
of a total of 275). SNP effects proved to be enhanced by
the adjustment for nongenetic covariates (a phenomenon
Table 3. Non-genetic characteristics and lipid profiles of the case–control
sample (CCS) compared with subjects excluded due to insufficient blood for
DNA analyses
CCS
(n¼ 371)
Excluded
(n¼ 79)
Categorical variable na (%) na (%) Pb
Case–control status Cases 186 (50) 40 (51)
Controls 185 (50) 39 (49) 0.94
Gender Men 170 (46) 41 (52)
Women 201 (54) 38 (48) 0.33
Education University 135 (36) 25 (32)
Secondary 210 (57) 47 (59)
Primary 26 (7) 7 (9) 0.67
Country of Switzerland 200 (54) 40 (59)
birth Othersc 117 (31) 23 (21)
Mediterraneanc 54 (15) 16 (20) 0.45
Cigarette Never 174 (47) 32 (41)
smoking Ex-smoker 104 (28) 21 (27)
Current 89 (24) 26 (33) 0.27
Physical activity Actived 137 (37) 19 (24)
Sedentaryd 234 (63) 60 (76) 0.029
Continuous variable Mean (SD) Mean (SD) Pb
Age (years) 50.6 (9.8) 49.2 (10.3) 0.18
BMI (kg/m2) 24.8 (3.9) 25.0 (3.6) 0.47
Dietary fat (%) 35.1 (7.0) 35.2 (6.8) 0.82
Dietary fiber
(g/day)
16.1f (0.5) 14.5f (0.5) 0.080
Alcohol drinking
(g alcohol/day)e
10.6f (1.0) 12.8f (0.5) 0.17
Lipid profile
(mmol/l)
Total
cholesterol
5.81 (1.0) 5.85 (1.0) 0.75
HDL-
cholesterol
1.40 (0.4) 1.36 (0.4) 0.40
LDL-
cholesterol
3.81 (1.1) 3.88 (1.1) 0.59
Triglycerides 1.15f (0.5) 1.13f (0.6) 0.68
aTotals may vary due to missing values.
bk-category variables: w2 test (k7 1 d.f.) P-value; continuous variables:
minimum P-value for Student’s t and Wilcoxon rank sum tests.
cOthers: mostly France (approximately one-third), remainder <5% each;
Mediterranean: Italy, Portugal, Spain.
dActive (sedentary): 10% (<10%) of total energy in activities requiring
4 basal metabolic rate.
eTotal (beer þ wine þ hard liquor) among drinkers [% CCS/excluded: 88%/
82% (P¼ 0.21)].
fGeometric mean (SD of log data).
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termed ‘negative confounding’ in epidemiology). Finally, we
employed bootstrapping and cross-validation techniques to
address some of the biases expected from our analytical
procedures. On the other hand, the study also had its
limitations. It was exploratory in nature. Our logistic regression
modeling strategy systematically attempted to minimize the
set of SNPs over multiple models without correction. Thus,
we accept that some parts of the findings are likely to be
false positive. However, our study succeeded in generating
hypotheses to guide further experimentation, either in an exten-
sion of our current sample, or in other independent samples.
In conclusion, we have reported on an exhaustive survey
of genetic variation spanning 11 candidate genes, all of which
are known to produce proteins that play key roles in the
homeostatic regulation of blood lipid profiles related to
cardiovascular health and disease. The study compared subjects
with extreme atherogenic or atheroprotective lipid profiles from
a major, ongoing epidemiological study of a population-based
random sample in Geneva, Switzerland. Each individual was
thoroughly characterized for known risk factors for CVD and
related blood lipid profiles. Our findings implicate a subset of
nine of the 275 genetic variants, spanning seven candidate
genes, together with five of the 10 environmental factors, in the
etiology of the complex trait in our sample. We have proposed a
model involving these 14 risk factors that merits evaluation in
future independent studies.
Table 4. Reverse cholesterol transport (RCT) SNPs retained within groups of atherogenic, atheroprotective, and gender-dependent SNPs using (nominal) P¼ 0.10
stepdown logistic model SNP selection (10 non-genetic covariates forced into model)
Entry stepb r2 adjustedc Correct classification (%)d Final model significancec
Total Cases Controls P OR (95% CI)
Atherogenic
SNPs in final modela
None (covariates only) 0 0.41 73 74 73
APOE4 1 0.44 76 74 78 0.0009 3.58 (1.69–7.56)
CETP 1b.629 2 0.46 75 74 76 0.0085 2.50 (1.26–4.93)
APOA1 2b.þ33 3 0.47 75 75 76 0.0246 2.40 (1.12–5.15)
ABCA1 32b.þ30 4 0.49 74 74 74 0.0374 2.31 (1.05–5.07)
LPL 6b.þ82 5 0.50 75 72 78 0.0450 2.08 (1.02–4.25)
EL 10b.337 6 0.51 77 74 80 0.0812 1.92 (0.92–3.98)
Atheroprotective
SNPs in final modelf
None (covariates only) 0 0.41 74 72 75
APOE2 1 0.49 76 77 75 <0.0001 0.10 (0.04–0.28)
PLTP 10b.þ70 2 0.53 77 78 77 0.0005 0.13 (0.04–0.41)
LPL S447X 3 0.56 77 76 79 0.0006 0.22 (0.10–0.53)
ABCA1 50b.3038 4 0.58 77 77 77 0.0007 0.15 (0.05–0.45)
CETP 6b.56 5 0.61 79 79 78 0.0055 0.34 (0.16–0.72)
HL 5b.98 6 0.62 78 78 79 0.0446 0.43 (0.19–0.98)
HL 1b.280 7 0.63 78 78 77 0.0248 0.44 (0.22–0.90)
LDLR2 (rs2228671) 8 0.64 77 78 76 0.0621 0.45 (0.20–1.04)
Gender-dependent
SNPs in final modelg
None (covariates only) 0 00.41 73 71 75
PLTP 1b.þ26 þ gender interaction 1 0.43 74 74 74 0.6215m 0.77m (0.27–2.19)m
2 0.45 73 71 75 0.0009w 0.11w (0.03–0.40)w
ABCA1 50b.2037 þ gender interaction 3 0.45 74 73 75 0.0519m 2.96m (0.99–8.82)m
4 0.46 74 71 76 0.6592w 0.80w (0.31–2.12)w
EL 10b.504 þ gender interaction 5 0.46 74 73 75 0.0369m 0.35m (0.13–0.94)m
6 0.47 76 73 79 0.3614w 1.50w (0.63–3.58)w
SR-BI A350A þ gender interaction 7 0.47 75 73 78 0.0263m 0.30m (0.10–0.87)m
8 0.48 77 75 79 0.1363w 2.24w (0.78–6.48)w
ABCA1 1b.1126 þ gender interaction 9 0.48 77 75 79 0.1296m 2.19m (0.79–6.06)m
10 0.50 75 74 77 0.0312w 0.29w (0.09–0.89)w
HL 3b.279 þ gender interaction 11 0.50 75 73 77 0.1034m 0.42m (0.15–1.19)m
12 0.52 76 75 77 0.1099w 2.22w (0.84–5.91)w
aSubjects with complete data in tier 2 analysis of atherogenic SNPs: 159/186 cases, 160/185 controls (total 319/371).
bOrder of forced-forward entry of SNPs retained in model after (nominal) P¼ 0.10 backward elimination.
cAdjusted r2¼ raw r2/max(r2), where: Raw r2¼ 17 [L(0)/L(fitted)]2/n; L¼ likelihood (null versus fitted model), max (r2)¼ 17 L(0)2/n.
dOne-step approximation to leaving-one-out method. Case classification cutpoint: adjusted logistic probability of being a case 0.50.
ep¼ single SNP P-value (1 d.f. w2) adjusted for covariates and other SNPs in final model; OR (95% CI)¼ final model covariate-adjusted case/control SNP odds
ratio (95% confidence interval).
fSubjects with complete data in tier 2 analysis of atheroprotective SNPs: 145/186 cases, 145/185 controls (total 271/371).
gSubjects with complete data in tier 2 analysis of gender-dependent SNPs: 142/186 cases, 145/185 controls (total 287/371); for each gender-dependent SNP main effect
listed, the corresponding SNP gender interaction term was included in the model; both main effect and interaction terms were used to calculate gender-specific ORs.
m,wResults shown separately for menm and womenw for gender-dependent SNPs.
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MATERIALS AND METHODS
Subjects
The population, sample recruitment and data collection
methods have been described in detail elsewhere (9,44). In
brief, survey respondents were randomly selected within
gender/age strata throughout January 1999 to December 2000
from the resident population of Geneva, Switzerland aged
35–74 years. The present study sample comprises 846 men and
862 women not under treatment for hypercholesterolemia (total
n¼ 1708 untreated study subjects).
A subset of 450 phenotypically extreme subjects was selected
from the untreated subjects on the basis of their HDL-C and
LDL-C concentrations falling in the lowest and highest tertiles
(T1, T3¼ 33.3rd, 66.7th percentiles) separately by gender. The
tertile boundaries (mmol/l) for HDL-C and LDL-C were (men/
women): HDL-C, T1¼ 1.06/1.33, T3¼ 1.32/1.63; LDL-C,
T1¼ 3.54/3.22, T3¼ 4.30/4.04 (to convert to mg/dl, multiply
by 38.6).There were 226 (13.2%) subjects with HDL-CT1
and LDL-C>T3 (low HDL, high LDL), which was considered
an atherogenic phenotype. At the other extreme, there were 224
(13.1%) subjects with HDL-C>T3 and LDL-CT1 (high
HDL, low LDL). However, 79 subjects had to be excluded
from further study because of too little or no blood sample
remaining for genetic analyses. The initial blood samples from
these excluded subjects had not been used for any other studies.
The final sample size was n¼ 371, comprising 186 ‘cases’
(atherogenic phenotypes) and 185 ‘controls’ (non-atherogenic
phenotypes), comprising 11.4% each of the 1629 subjects with
available DNA data.
Survey procedures
Respondents completed questionnaires and were examined in a
mobile epidemiology clinic by trained health technicians.
Blood pressure, height and weight were measured and venous
blood was drawn. Diet and physical activity were recorded
using semi-quantitative food and physical activity frequency
questionnaires previously developed and validated in the same
population (42,43). Total plasma cholesterol and TG and their
concentrations in the lipoprotein subfractions were assayed in
fasting blood (Bayer Technicon Diagnostics, Brussels, Belgium).
Total genomic DNA was extracted from EDTA blood (Gentra
Puregene blood kit, BioConcept, Allschwil, Switzerland).
LDL-C (mmol/l) was calculated as (total cholesterol7HDL-
C7TG/2.2) (45).
Table 5. Contributions of reverse cholesterol transport (RCT) SNPs and nongenetic covariates to case–control lipid profile status in tier 4 logistic model (nominal)
P¼ 0.05 stepdown selection of both SNPs and covariates, with bootstrap validation of final model P-values and adjusted odds ratios
SNPs and covariates retained
in final model
Entry stepa r2 adjustedb Correct classification (%)c 9-SNP þ 5-non-genetic covariate
tier 4 final logistic modeld
Total Cases Controls P OR (95% CI)
BMI (kg/m2) 1 0.27 71 69 73 <0.0001 1.65 (1.43–1.98)
APOE2 2 0.32 74 74 74 0.0002 0.14 (0.03–0.33)
PLTP 1b.þ26 3 0.35 72 73 72 0.0053 0.27 (0.08–0.61)
Alcohol: medium þ high 4 0.38 74 77 72 <0.0001 0.02 (0.001–0.08)
Alcohol: low 5 0.42 73 74 72 0.0011 0.11 (0.02–0.30)
Current smoker 6 0.45 76 78 74 0.013 6.42 (2.06–16.6)
ABCA1 50b.3038 7 0.48 78 80 76 0.0032 0.20 (0.05–0.48)
LPL S447X 8 0.50 77 77 78 0.031 0.41 (0.14–0.86)
Age (years) 9 0.51 76 77 76 0.072 1.04 (0.997–1.09)
Gender (women) 10 0.53 78 79 78 0.012 0.11 (0.05–0.50)
ABCA1 32b.þ30 11 0.54 77 77 78 0.030 3.80 (1.20–9.83)
LDLR2 (rs2228671) 12 0.55 78 77 80 0.042 0.38 (0.11–0.89)
HL 1b.280 13 0.56 77 77 78 0.039 0.46 (0.18–0.94)
HL 3b.279 14 0.56 77 75 78 0.039m 0.34m (0.08–0.92)m
HL 3b.279Gender 15 0.57 78 78 79 0.13w 2.86w (0.79–7.74)w
SR-BI A350A 16 0.57 78 78 78 0.034m 0.28m (0.05–0.82)m
SR-BI A350AGender 17 0.60 78 79 78 0.053w 4.98w (1.03–15.9)w
Analyses based on 149/186 cases, 152/185 controls (301/371) with complete data on all covariates and 10 tier 3 selected SNPs.
aOrder of forced-forward entry of SNPs and nongenetic covariates retained in model after (nominal) P¼ 0.05 backward elimination (pre-bootstrap).
bAdjusted r2¼ raw r2/max(r2), where: raw r2¼ 17 [L(0)/L(fitted)]2/n, L¼ likelihood (null versus fitted model), max (r2)¼ 17L(0)2/n (pre-bootstrap).
cOne-step approximation to leaving-one-out method. Case classification cutpoint: adjusted logistic probability of being a case 0.50 (pre-bootstrap).
dBootstrapped single-SNP or covariate odds ratio (OR) with 95% CI (bootstrap percentile confidence interval) adjusted for all other SNPs and covariates in model
(B¼ 2000 bootstrap replicates). Test-based P-value (assuming H0: OR¼ 1) derived from bootstrapped log(OR).
m,wResults shown separately for menm and womenw for gender-dependent SNPs.
Table 6. Tier 4 model estimated correct classification rates, with internal cross-
validations in five 80:20% random subsamples
Subgroup Total samplea Correct classification
rates (%)
Subsample mean
Random subsampleb
A B C D E
Cases 78 80 68 68 59 83 72
Controls 79 76 72 69 75 87 76
Total 78 78 70 69 67 85 74
aOne-step approximation to leaving-one-out method; case classification
cutpoint: adjusted logistic case probability 0.50.
bCross-validation of model based on 80% random subsample obtained by
classifying the 20% random subsample of excluded subjects (same cutpoint as
in footnote a).
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Laboratory procedures
Primers for genomic amplification were chosen outside the
exon sequence. Each exon, along with intronic 50 and 30 ends
(total 67 948 bp), was amplified separately and sequenced.
Amplification primers are available upon request.
The entire coding DNA and the immediately adjacent
noncoding DNA, including both 50- and 30-UTR and a portion
of each intron, were assayed first in a purposefully selected
resequencing subsample of n¼ 95 subjects in whom the largest
genetic variability was anticipated: 48 subjects had a non-
atherogenic lipid profile and were sedentary (see below), hence
were expected to have a ‘protective’ genetic constitution, while
the 47 other subjects had an atherogenic lipid profile but were
physically active, hence were expected to have a ‘deleterious’
genetic constitution.
DNA from the resequencing subsample was amplified across
exons (excluding LDLR, see below) using the Perkin Elmer
Gene Amp PCR system 9600 as described in detail elsewhere
(46). PCR amplification products were purified and sequenced
in both directions, using big dye-terminator chemistry and
373-XL automated sequencers (ABI). Sequence comparisons
were determined using the Sequencher Program version 4.1.2
(Gene Codes) and verified by visual inspection. Final
determinations were made based on the presence of two peaks,
each of which was approximately half the size of the correspond-
ing homozygous peak. Manual confirmation was required due
to complications from sequence irregularity and preferential
PCR amplification of one allele over the other. For LDLR, we
retrieved the information from public databases, mostly from
Cargill et al. (47).
Statistical power for SNP detection
The sequencing component of this study had 99.9% (95%)
power for detecting a SNP with rare allele frequency 5%
(1%), based on 95 subjects (48). We therefore decided to
assay all SNPs with rare allele frequency 3% in the remaining
cases and controls. Variants identified were assayed in the
larger sample using a modified template-directed dye-termi-
nator incorporation with fluorescence polarization (TDI-FP)
detection (Acycloprime-FP SNP Detection Kit of PerkinElmer
Life Sciences, Inc.). Primers to amplify and detect SNPs are
available upon request.
Adjustment of single- and multi-SNP odds ratios
(OR) for covariates and SNP coding
We used logistic regression models for assessing single and
simultaneous SNP effects adjusted for multiple nongenetic
covariates. The covariates were: gender, age (years), body
mass index (BMI, kg/m2), education [reference group¼ primary
(<9 years schooling), secondary, university (13 years and Swiss
baccalaureate)], country of birth {reference¼ Switzerland þ all
other [approximately one-third France, remainder (mostly
Northern Europe) <5% each)], Mediterranean (Italy, Spain,
Portugal)}, cigarette smoking {reference¼ [never (<100
lifetime cigarettes) þ exsmoker (quit 1 year pre-interview)],
current}, alcohol drinking (g alcohol/day) [reference¼ none, low
(men/women: 1–40/1–20), medium þ high (men/women: 41þ/
21þ)], total dietary fat (%), dietary fiber (g/day), and daily energy
expenditure {reference¼ active [10% total energy expended in
physical activities requiring four or more times the basal
metabolic rate (4BMR) (49)], sedentary (<10% in 4BMR)}.
Overall, the 10 non-genetic covariates were expressed with 12
variables.
Each SNP was coded 0 if the rare variant was absent, and 1 if
present (as heterozygote/homozygote). This coding assumes
the rare allele effect is dominant. As homozygotes for the rare
allele were extremely rare, it is essentially the same thing as an
additive model, consistent with most evidence about the
genetics of many quantitative traits. The correlation between
two SNPs was assessed by Pearson’s r statistic, equivalent to a
standardized linkage disequilibrium (LD) coefficient (36). We
used r mainly to avoid multi-collinearity in the logistic
modeling (see below), not to assess LD, per se.
The outcome of the logistic regression was the probability of
being a ‘case’, that is, of having an atherogenic lipid profile.
The odds ratio (OR) of being a case (atherogenic) versus
control (non-atherogenic) with 95% confidence interval (CI)
was calculated. All covariates were entered as linear terms
either as continuous or dummy indicator variables as listed
above. The adjustment for covariates was done to neutralize
potential confounding effects of variables that are related to the
outcome and are distributed differently in cases versus controls.
Single- and multi-SNP adjusted logistic models
The individual SNP data were analyzed first with crude
(unadjusted) case/control ORs, and next with single-SNP ORs
from logistic models adjusted for the non-genetic covariates in
which the outcomewas case–control status and each SNP was the
explanatory variable of interest. We then employed a four-tiered
modeling strategy, summarized in Table 1, to investigate the
simultaneous associations of the SNPswith extreme lipid profiles:
Tier 1 modeling strategy
Tier 1a. The individual SNPs were divided into three mutually
exclusive groups: SNPs with individual case–control adjusted
odds ratios (OR) 1.50 were considered ‘atherogenic’, and
those with OR 1/1.50¼ 0.67 were considered ‘atheroprotec-
tive’. SNPs with gender interaction (nominal) P 0.10 and for
which at least one of the latter conditions was satisfied by either
men or women or both (usually differently in each gender), were
considered ‘gender-dependent’ (overriding the first two SNP
groups), and the interaction term was used in subsequent mod-
eling to obtain the corresponding gender-specific results.
Tier 1b. Further exclusions within the three Tier 1a SNP
groups were made for: (i) highly correlated SNPs (jrj  0.7,
within or between groups); (ii) SNPs with rare allele frequency
5% (due to small sample sizes, although we could detect
SNPs with frequencies 3% in the resequencing subsample
with excellent power, the logistic regression model coefficients
were unstable for SNPs with frequency 5%). In the presence
of high correlation between an exonic and an intronic/flanking
region/UTR SNP, we retained the exonic SNP for modeling
whether it coded for a synonymous or non-synonymous amino
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acid change (31). For highly correlated non-exonic SNPs, arbi-
trary choices of which SNP to include in the modeling process
were made. There was one exception for EL: the coding
exon 3b.53 (T111I) SNP was not initially classified as
gender-dependent (interaction P¼ 0.21). However, because of
very high correlation (r¼ 0.96) with the non-coding gender-
dependent intronic 4b.þ98 SNP (interaction P< 0.05), T111I
was substituted for 4b.þ98 in the modeling.
Tier 2 modeling strategy
Within each of the three tier 1a SNP groups, all tier 1-retained
SNPs were eligible for stepdown selection using (nominal)
P¼ 0.10 in a logistic model in which the 10 non-genetic
covariates were forced to remain. For gender-dependent SNPs,
the SNP gender interaction term was eligible to be removed
if the SNP main effect was in the model, and an SNP main
effect removal implied simultaneous removal of the interaction
term. Except for occasional missing data, the three tier 2
within-SNP group analyses were performed on the same
sample of subjects.
Tier 3 modeling strategy
All tier 2-retained atherogenic, atheroprotective, and gender-
dependent SNPs were jointly eligible for stepdown selection
using (nominal) P¼ 0.05 in a logistic model in which the 10
non-genetic covariates had been forced to remain.
Tier 4 modeling strategy
All tier 3-retained SNPs and the 10 non-genetic covariates were
jointly eligible for stepdown selection using (nominal) P¼ 0.05
in a logistic model.
The predictive contributions of the SNPs and non-genetic
covariates retained in the tiers 2–4 logistic models were
assessed by the cumulative adjusted coefficient of determina-
tion (squared multiple correlation), r2 (50). For this purpose the
stepdown-retained SNPs/covariates were forced into the model
in the order that they would have been entered using forward
selection. We also calculated the cumulative overall and case–
control-specific correct classification rates using a one-step
approximation to the leaving-one-out method (case-cutpoint:
adjusted case probability >0.50).
In order to validate the final tier 4 logistic regression model
SNP and non-genetic covariate P-values and ORs, a standard
Monte Carlo bootstrap (resampling with replacement) proce-
dure based on 2000 replicates was applied (51). The potential
impact of population stratification on the findings was assessed
by refitting the tier 4 logistic model to Swiss-born subjects only
and comparing the results to those from the final model based
on all subjects.
Internal cross-validation of tiers 1–4 logistic models
In order to assess replicability of the logistic modeling process,
the entire four-tiered modeling strategy was internally cross-
validated by applying it to five 80 : 20% random partitions of
the dataset. The cases and controls were first randomly ordered
separately within gender, and each of the four resulting
randomly permuted subgroups was divided into fifths and
recombined into five different 80 : 20% split datasets. The
complete tiers 1–4 modeling strategies were then applied to
each of the five 80% subsamples to provide comparisons with
the total sample results. Finally, each 20% subsample excluded
from the modeling process was classified into cases and
controls using the tier 4 model based on the corresponding
80% subsample.
Statistical power of the case–control association study to
detect single-SNP ORs 6¼ 1
We described above the statistical power to detect SNPs in the
resequencing sample of n¼ 95 subjects. Here we describe the
statistical power to detect non-null SNP effects with the case–
control sample of n¼ 371 subjects. The latter is a function of
the true effect size of the SNP and of its rare allele frequency
(Appendix Figure B). For example, statistical power (1-b) was
80% (given two-tailed a¼ 5%) to detect single-SNP ORs
ranging from 1.75 to 2.00 (or 0.50 to 0.57) for rare allele
frequencies 17.5%, from 2.10 to 2.30 (or 0.44 to 0.48) for
frequencies between 10 and 15%, and from 2.30 to 2.90 (or
0.35 to 0.44) for frequencies between 5 and 10%.
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